Entering text into the input field will update the search result below

Atea Pharmaceuticals, Inc. (AVIR) Q2 2023 Earnings Call Transcript

Aug. 08, 2023 10:04 PM ETAtea Pharmaceuticals, Inc. (AVIR)
SA Transcripts profile picture
SA Transcripts

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET

Company Participants

Jonae Barnes – Senior Vice President of Investor Relations and Corporate Communications

Jean-Pierre Sommadossi – Chief Executive Officer and Founder

Janet Hammond – Chief Development Officer

Arantxa Horga – Chief Medical Officer

Andrea Corcoran – Chief Financial Officer and Executive Vice President of Legal

John Vavricka – Chief Commercial Officer

Conference Call Participants

Maxwell Skor – Morgan Stanley

Jessica Hui – Evercore

Nik Gasic – Leerink Partners


Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Second Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions.

I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Ms. Barnes, please proceed.

Jonae Barnes

Thank you, operator. Good afternoon, everyone, and welcome to Atea Pharmaceuticals second quarter 2023 financial results and business update conference call. Earlier today, we issued a press release, which outlines the topics we plan to discuss. You can access the press release as well as the slides that we will be reviewing today by going to the Investors section of our website at ir.ateapharma.com.

With me from Atea are our Chief Executive Officer and Founder, Dr. Jean-Pierre Sommadossi; Chief Development Officer, Dr. Janet Hammond; Dr. Arantxa Horga, Chief Medical Officer; Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran; and our Chief Commercial Officer, John Vavricka. They will all be available for the Q&A portion of today’s call.

Before we begin the call, as outlined on Slide 2, I would like to remind you that today’s discussion will contain forward-looking statements that

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About AVIR

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on AVIR

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.